Dec. 7, 2015
Description:
Metformin, a naturally-occurring biguanide, is an FDA-approved high-safety profile diabetes drug that has been used extensively for decades. Researchers at Iowa State University and Medical College of Wisconsin synthesized Mito-Met, a mitochondria-targeted analog of metformin and then evaluated the preclinical efficacy of Mito-Met in cell culture and MitoPark animal models of Parkinson’s disease. It was demonstrated that Mito-Met improved motor deficits in MitoPark mice and that it was a neuroprotective agent that exceedingly qualifies for in-depth preclinical efficacy and toxicology evaluations for treating mitochondrial diseases including Parkinson’s disease.
Human Therapeutics, Treatment of Parkinson’s disease
• Increases the survival of dopaminergic neurons in cell culture and in a mouse model of Parkinson’s disease
• Based on FDA-approved low-toxicity drug
• Chemical modifications increased its affinity to the intended mitochondrial target
• Addresses a high value market
• Effective at very low doses
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
iowa state university
treating mitochondrial diseases
mitopark animal models
wisconsin synthesized mito-met
in-depth preclinical efficacy
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium